摘要
原发性肝癌是临床上常见的恶性肿瘤之一,其发病率和死亡率高。虽然数十年来,肝癌的诊断和治疗在不断发展,但目前肝癌的诊断仍主要依赖于影像学、组织活检和甲胎蛋白(AFP)等肿瘤标志物。受限于上述检测手段的特异性和灵敏性,70%的患者在确诊时已经失去手术机会,故目前肝癌的整体预后仍然很差。因此,如何实现早期诊断,实施精准个体化治疗对提高肝癌的整体预后至关重要。液体活检主要包括循环肿瘤细胞(CTC)和游离DNA(cfDNA),以其微创,取材方便,可重复检测,动态监测等优势,有望在早期诊断、动态监测、评估预后和治疗效果、药物筛选等方面发挥重要作用。
Hepatocellular carcinoma(HCC)is one of the most common clinical malignancies with high morbidity and mortality.Although the diagnosis and treatment of HCC has been developing for decades,the diagnosis of HCC still mainly relies on imaging biopsy and tumor markers such as alpha-fetoprotein(AFP).Due to the specificity and sensitivity of the above tests,70%of patients are ineligible for operation when diagnosed definitely,so the overall prognosis of HCC is still very poor now.Therefore,how to achieve early diagnosis and implement accurate individualized treatment is crucial to improve the overall prognosis of HCC.Liquid biopsy mainly includes circulating tumor cell(CTC)and cell-free DNA(cfDNA).Due to the advantages of minimal invasiveness,convenience,repeatable test,dynamic monitoring,liquid biopsy is expected to become the main methods assisting early disease diagnosis,dynamic monitoring,assessment of prognosis and drug screening etc.
作者
周江敏
侯炳武
王金林
张志伟
Zhou Jiangmin;Hou Bingwu;Wang Jinlin;Zhang Zhiwei(Department of Liver Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2020年第10期1979-1982,共4页
Chinese Journal of Experimental Surgery
关键词
液体活检
循环肿瘤细胞
游离
DNA
循环肿瘤
DNA
原发性肝癌
Liquid biopsy
Circulating tumor cell
Cell-free DNA
Circulating tumor DNA
Hepatocellular carcinoma